Study S000196

Preoperative Tirzepatide for Bariatric Surgery

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06721507
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: RECRUITING
Enrollment: 50
Start: 2025-03-27
Primary completion: 2026-12-31
Lead sponsor: Marlene Starr
Conditions: Obesity and Obesity-related Medical Conditions; Bariatric Surgery
Interventions: DRUG:tirzepatide; BEHAVIORAL:Standard of Care
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change in inflammatory markers c reactive protein (CRP) [Baseline and 3 months post-drug]
Change in inflammatory markers interleukin 6 (IL-6) [Baseline and 3 months post-drug]
Change in inflammatory markers tumor necrosis factor (TNF) [Baseline and 3 months post-drug]
change in inflammatory markers (leptin) [Baseline and 3 months post-drug]
change in inflammatory markers (adiponectin) [Baseline and 3 months post-drug]
change in inflammatory markers renin-angiotensin-aldosterone system (RAAS) [Baseline and 3 months post-drug]
RNA sequencing [at time of surgery]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0016563	Preoperative Glucagon-like Peptide-1 Therapy in Bariatric Surgery Patients With Morbid Obesity (PreMO): Rationale and Study Design for a Randomized Controlled Trial. Jain V, The Journal of surgical research	2026	Protocol	PMID 41643256 DOI	cites ClinicalTrials.gov:NCT06721507; registry reference DERIVED:41643256